SIMAP

SIMAP will develop a simulation model of the cancer related MAP-kinase pathway, integrating and analyzing data from various types of resources, which may assist in the development of better cancer treatment.

The completion of the human genome gave hope for a new age of medical understanding, but 4-5 years later costs of drug development are still rising and the success rate has not improved. Drugs that have already hit the market are found to have major side effects not perceived in the past and are often given to patients without discrimination on their likeliness to respond.

Large scale methodologies that thrive in recent years, allowed the industry and academia to gather more information on RNAs and proteins. However, the understanding of the molecular and cellular processes is still lacking, not to mention the connection to the clinical outcome. In order to fully use this data, a comprehensive integration and modelling effort is needed. A systematic rational hypothesis-driven research approach connecting all those levels of information is a much needed computational tool. This is the main goal of SIMAP project.

The ultimate goal of SIMAP is to develop a comprehensive simulation biochemical model of EGFRMAP kinase pathway in connection to cancer clinical information. SIMAP will:

  • Incorporate low-level biochemical modelling of individual molecules;
  • Simulate the behaviour of the pathway;
  • Add genomic and proteomic data;
  • Incorporate individual patients’ responses; and
  • Analyze sub population of responses in the context of the biochemical behaviour and genotype data

For further information, please visit:
http://www.simap-project.org

Project co-ordinator:
Compugen Ltd.

Partners:

  • Aureus Pharma, (FR)
  • Compugen Ltd., (IL)
  • Consejo Superior de Investigaciones Científicas, (ES)
  • Halevi Dweck & Co.Arttic Israel Company Ltd., (IL)
  • Fundacio Institut De Recerca De L'Hospital Universitari Vall D'Hebron, (ES)
  • Fondazione IRCCS Istituto Nazionale Dei Tumori, (IT)
  • The Max-Planck Institute for Infection Biology, (DE)
  • The University of Glasgow, (UK)
  • The Weizmann Institute of Science, (IL)

Timetable: from 01/06 – to 12/08

Total cost: € 4.464.201

EC funding: € 3.126.662

Instrument: STREP

Project Identifier: IST-2004-027265

Source: FP6 eHealth Portfolio of Projects

Most Popular Now

NHS and Patients to Benefit from New Par…

IMS MAXIMS and Secure Exchange Solutions have announced a partnership to offer mobile, secure and cost-effective provider-to-provider and provider-to-patient communications to NHS organisations, GP practices and patients.

Bayer is Taking Collaboration with Healt…

As a pioneer when it comes to collaborating with digital health start-ups, Bayer is now taking the next step. Instead of one-off startup programs, it is now focusing on collaborating...

International Master's in Digital Health

The Master of Science (M.Sc.) in Medical Informatics (MMI) at European Campus Rottal-Inn (ECRI) in Pfarrkirchen - a branch of the Deggendorf University of Applied Sciences (THD - Technische Hochschule...

New Antibiotics Are Desperately Needed: …

As the threat of antibiotic resistance looms, microbiologists aren’t the only ones thinking up new solutions. James Zou, PhD, assistant professor of biomedical data science at Stanford, has applied machine...

Digital Medicine: The Opportunities and …

9 - 11 April 2019, Berlin, Germany. Be it preventive healthcare for dementia using intuitive apps, anonymous hospital hygiene inspections using IoT sensors, or VR applications that let hemiplegic patients live...

Highland Marketing Forms Alliance with E…

An alliance between Highland Marketing and Experiential HealthTech will be announced at this year's Digital Health Rewired, with both companies exhibiting from stand B14. Highland Marketing is a full-service marketing...

Google Research Shows How AI can Make Op…

As artificial intelligence continues to evolve, diagnosing disease faster and potentially with greater accuracy than physicians, some have suggested that technology may soon replace tasks that physicians currently perform. But...

Virtual Reality could be Used to Treat A…

Playing games in virtual reality (VR) could be a key tool in treating people with neurological disorders such as autism, schizophrenia and Parkinson's disease. The technology, according to a recent...

Open Call SC1-HCC-02-2019: Support for t…

In the past years several open service platforms for Active and Healthy Ageing domains have been developed, originating from the medical, independent living, and IoT domain. These platforms aim at...

The Moore Blatch Silicon Cup Opens for E…

This year's Moore Blatch Silicon Cup has been launched and is now open for IT companies to enter. The event takes place over 26 - 27 September on the Isle...

MEDICA 2019: Clear Focus on Future Topic…

18 - 21 November 2019, Düsseldorf, Germany. As a result of the final phase of exhibitor registrations for the world’s leading medical trade fare MEDICA 2019 in Düsseldorf, one thing is...